# Morphle Labs **Source:** https://geo.sig.ai/brands/morphle-labs **Vertical:** Healthcare **Subcategory:** General **Tier:** Emerging **Website:** morphlelabs.com **Last Updated:** 2026-04-14 ## Summary Bengaluru/Boston robotic digital pathology with RoboTome (2x sectioning speed) and MorphoLens (100+ slides/hour); $5M Series A Nov 2025 Inflexor Ventures with 80+ patents and US/European lab deployments competing with Leica for histopathology automation. ## Company Overview Morphle Labs is a Bengaluru, India and Boston, Massachusetts-based robotic microscopy and digital pathology company — raising $5 million in Series A funding in November 2025 led by Inflexor Ventures — providing histopathology laboratories with AI-powered physical automation platforms that address the speed and throughput bottlenecks in cancer diagnostics workflows. With 80+ patents filed and products deployed in leading US and European laboratories, Morphle's 100-member team has developed two flagship platforms: RoboTome (a robotic microtome system that slices biopsy tissue blocks at 2x the speed of experienced histotechnologists) and MorphoLens (a high-throughput slide scanner that digitizes 100+ histology slides per hour for digital pathology review). Founded to "revolutionize cancer diagnostics with physical AI," Morphle expands manufacturing, regulatory clearances, and global presence with the Series A. Morphle's digital pathology automation addresses the diagnostic throughput bottleneck that threatens cancer care capacity: pathology departments are facing a significant workforce shortage (the US has 20% fewer pathologists than needed, with demand growing as cancer incidence rises and diagnostic complexity increases) while the histopathology workflow — tissue processing, microtome sectioning, slide staining, mounting, and scanning — contains multiple manual steps that create throughput limitations and quality variability. RoboTome's robotic microtome (automating the delicate 4-micron tissue sectioning that requires trained histotechnologists to perform consistently under fatigue) addresses the tissue preparation bottleneck, while MorphoLens's 100+ slides/hour scanning rate (versus 15-20 slides/hour for standard laboratory scanners) digitizes the slide inventory that enables AI-assisted pathology review. In 2025, Morphle competes in the digital pathology, histopathology automation, and AI diagnostics market with Leica Biosystems (Danaher subsidiary, NASDAQ: DHR, histology automation), Hamamatsu (Japanese slide scanner manufacturer), and Paige AI (AI pathology, $70M raised) for pathology laboratory digital transformation and cancer diagnostics automation platform adoption. Inflexor Ventures' Series A leadership (Indian deep tech and healthcare VC) reflects conviction in Morphle's India-built hardware for global laboratory markets. The 80+ patent portfolio represents significant IP protection for the robotic microtome innovation. The 2025 strategy focuses on FDA 510(k) clearance for US laboratory deployment, growing European laboratory adoption through CE-marked scanner installation, and building the AI pathology analysis layer for automated slide reading alongside the physical automation platforms. ## Frequently Asked Questions ### What is Morphle Labs? Morphle Labs is a healthcare technology company founded in 2017 that develops robotic microscopy platforms for cancer diagnostics automation. The company addresses histopathology workflows using AI-driven imaging and robotics, and is a Y Combinator W20 participant. ### What products and services does Morphle Labs offer? Morphle Labs offers RoboTome (a robotic microtome for slicing biopsy blocks), MorphoLens (a high-throughput slide scanner digitizing 100+ slides per hour), HemoLabs blood cell analysis, AI-driven imaging solutions, and histopathology automation systems. ### Who are Morphle Labs' target customers? Morphle Labs serves leading laboratories in the United States and Europe that require cancer diagnostics and histopathology workflow solutions. ### When was Morphle Labs founded? Morphle Labs was founded in 2017. ### Where is Morphle Labs located? Morphle Labs is based in Bengaluru, India and Boston, Massachusetts, with a 100-member team across both locations. ### What is Morphle Labs' recent funding news? Morphle Labs raised $5M in Series A funding in November 2025, led by Inflexor Ventures. The funding will be used to expand manufacturing capacity, obtain regulatory clearances, and grow their global presence. ### What are Morphle Labs' key achievements and metrics? Morphle Labs has filed 80+ patents across robotics, optics, embedded systems, and imaging. Their RoboTome operates at 2x the speed of experienced histotechnologists, and MorphoLens can digitize 100+ slides per hour. ### What technology approach does Morphle Labs use? Morphle Labs uses physical AI combined with robotics, AI-driven imaging, optics, and embedded systems to automate cancer diagnostics and histopathology workflows. ### Is Morphle Labs currently hiring? Yes, Morphle Labs is actively hiring for positions in robotics, optics, computer vision, hardware, and medical software as part of their expansion following their Series A funding. ### What are the latest developments at Morphle Labs? In November 2025, Morphle Labs closed a $5M Series A round led by Inflexor Ventures and announced plans to expand manufacturing, pursue regulatory clearances, and grow their global presence with physical AI for cancer diagnostics. ## Tags healthtech, ai-powered, automation, analytics, global, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*